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Summary
Mycobacterium smegmatis strains that contain
inactivated EmbA or EmbB proteins are unable to
synthesize terminal Arab1/2Araa1/5(Arab1/
2Araa1/3)Araa1/5Araa1/(Ara6) motif in the cell
wall polysaccharide arabinogalactan. Instead, the mu-
tants contain a linear Arab1/2Araa1/5Araa1/
5Araa1/(Ara4) motif, suggesting that these proteins
are involved in the synthesis or transfer of the disac-
charide Arab1/2Araa1/ to an internal 5-linked Ara.
Therefore, we synthesized a linear Arab1/2Araa1/
5Araa1/5Araa1/5Araa1/ with an octyl aglycon as
an arabinosyl acceptor in cell-free assays. A facile as-
say was developed using the chemically synthesized
glycan, membrane, and particulate cell wall as the
enzyme source, and 5-phosphoribose diphosphate
pR[14C]pp as the arabinose donor. The results un-
equivocally show that two arabinofuranosyl residues
were added at the tertiary/5Araa1/ of the synthetic
glycan. This activity was undetectable in strains of
M. smegmatis where embB or embA had been geneti-
cally disrupted. Normal activity could be restored
only in the presence of both EmbA andEmbBproteins.
Introduction
D-arabinofurans are key components in the cell wall of all
mycobacterial species [1–3] and are present in two dis-
tinct settings. In mycolyl-arabinogalactan (AG), the ara-
binan is the point of attachment of mycolic acids, long-
chain branched fatty acids that are responsible for the
low permeability of the bacterial cell wall toward antibi-
otics [4, 5]. In the cell wall-associated lipoarabino-
mannan (LAM), the arabinan is nonmycolylated; instead,
it is capped with short mannose oligosaccharides in
slow-growing Mycobacterium or inositol phosphate in
Mycobacteriumsmegmatis [6]. The mycobacterial arabi-
nofurans are structurally unique among the polysaccha-
rides known in nature. They are homopolymers with intri-
cate branching pattern and are composed of the
biologically rare sugar D-Araf. Although D-Araf is in-
volved in the biosynthesis of ketodeoxyoctulosonic
acid (KDO) [7] as a component of lipooligosaccharides,
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3 These authors contributed equally to this work.it is rarely found outside the Actinomycetales. The cur-
rent structural model of AG-arabinan is depicted as
a composite of three Ara22mers directly attached to the
galactan backbone evolving from a seminal structural
study [8].
The nonreducing termini of the AG-arabinan has
a characteristic structural feature which is a terminal
hexaarabinofuranosyl (Ara6) motif, Arafb1/2Arafa1/
5(Arafb1/2Arafa1/3)Arafa1/5Arafa1/, where both
the terminal b-Araf and the penultimate 2-a-Araf serve
as the anchoring points for the mycolic acids. In contrast,
the nonreducing termini of the arabinan in LAM, a linear
tetraarabinofuranosyl (Ara4) motif, Arafb1/2Arafa1/
5Arafa1/5Arafa1/, is known to coexist with the
branched Ara6 termini. Through varying degree of man-
nose capping at its nonreducing terminal b-Araf, the ara-
binan in LAM plays pivotal immunomodulatory functions
in host-pathogen interactions and disease outcome.
Mycobacterial D-Araf originate from the pentose
phosphate pathway/hexose monophosphate shunt
and the donor of the D-arabinofuranosyl residues is de-
caprenyl phosphoryl-D-arabinose (C50-P-Araf; DPA) [9],
which is formed from 5-phospho-D-ribose diphosphate
[10] and not a nucleotide sugar. Given the complexity of
the arabinan in AG, a number of arabinosyltransferases
that utilize DPA are likely to exist.
Ethambutol (EMB), a drug extensively used in combi-
nation therapy against multidrug-resistant tuberculosis,
has been shown to affect arabinan metabolism [11–13],
although its precise mode of action is unknown. During
the course of identifying the target and mechanisms of
resistance of EMB, Belanger et al. [14] showed that the
proteins encoded by the mycobacterial genes embA
and embB conferred EMB resistance in M. smegmatis.
Importantly, it was also shown that EMB inhibited in vitro
formation of arabinan to about 50% in an assay using
endogenous acceptors and chemically synthesized
DPA as the donor of Araf units. This inhibition was less-
ened in strains overexpressing embB [14], suggesting
that the proteins encoded by the emb genes catalyzed
the addition of Araf residues to nascent arabinan.
Disrupted mutants of either embA or embB of M.
smegmatis proved to be viable. However, arabinosyla-
tion of AG in each mutant was considerably reduced
and, specifically, the formation of the nonreducing ter-
minal disaccharide b-D-Araf-(1/2)-a-D-Araf character-
istic of the arabinan of AG was markedly diminished [15],
again suggesting that the Emb proteins were intimately
associated with arabinan synthesis and could be arabi-
nosyltransferases.
Although the structural data from previous experi-
ments were sound, we lacked the ability to directly assay
arabinosyltransferase activity. Therefore, we designed
a molecule to act as an acceptor of enzymatically trans-
ferred Araf residues that would mimic the native struc-
ture of mycobacterial AG, and the terminal Ara6 in partic-
ular. This molecule is a linear pentamer with the structure
27, Arab1/2Araa1/5Araa1/5Araa1/5Araa1, as its
octyl glycoside. The pentamer 27 was initially designed
with two objectives in mind. (1) There is only one site
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Although the termini in AG comprising Ara6
and Ara17 have been well characterized, the
inner extension of Araf-(1/5)-a-Araf is
unknown.available for the physiologically relevant arabinosyl-
transferases to act. (2) The enzymatically synthesized
product can be digested with endoarabinanase isolated
fromCellulomonas gelida to yield the well-characterized
Ara6 motif (Figure 1), allowing unambiguous identifica-
tion of the product’s structure [16]. Use of this pentamer
would also allow us to probe the question of whether
EmbA and EmbB were directly involved in the terminal
Ara6 formation and whether these enzymes were func-
tionally coupled [17].
In this study, we demonstrate unambiguously that
a mycobacterial cell-free preparation from wild-type
M. smegmatis was able to catalyze b-D-Araf-(1/2)-
a-D-Araf transferase activity to a synthetic substrate.
This transferase activity was not detectable in strains
of M. smegmatis where either the embA or embB gene
has been genetically disrupted and was restored by mix-
ing the enzyme source from the two disrupted strains.
Results
A synthetic strategy of sequential addition of Araf resi-
dues to build an arabinosyl acceptor (compound 27)
was employed, using well-established thioglycoside
glycosylation reactions [18]. Protecting groups were
chosen such that once the oligosaccharide is assem-
bled, a one-step debenzylation would afford the desired
pentamer 27. Most of the manipulations of protection
and deprotection were carried out at the monosaccha-
ride level of the synthetic strategy, alleviating difficulties
in handling reaction/purification after assembly of the
pentasaccharide.
Synthesis of Building Block 8
Commercially available hemiacetal 2,3,5-tri-O-benzyl-D-
arabinofuranose was acetylated and then converted to
its p-thiocresol derivative in the presence of boron tri-
fluoride ether to give compound 3. The p-cresyl 2,3,5-
tri-O-benzyl-1-thio-a-D-arabinofuranoside 3 underwent
thioglycoside glycosylation with n-octanol in the pres-
ence of N-iodosuccinimide and silver trifluoromethane-sulfonate to yield the octyl glycoside (4-1 and 4-2), pre-
dominantly as an a:b anomeric mixture (29.6% b,
32.3% a after column chromatography). The benzyl pro-
tecting groups were removed by hydrogenolysis; the 5-
OH was selectively tritylated to form compound 6, which
was rebenzylated and then the trityl group removed us-
ing 5% trifluoroacetic acid (TFA) to yield the building
block/acceptor 8 in 41.6% yield after chromatography
(Figure 2).
Synthesis of Building Block 13
The C-5 OH of D-arabinose could be easily protected by
treatment with t-butyldiphenylsilyl chloride (TBDPSCl) to
give compound 9 in moderate yield. Acetylation and p-
thiocresylation gave compound 11. Deacetylation and
benzylation afforded the fully protected building block
donor 13, which could be selectively deprotected at the
5-position for further modification. Except for the initial
step of selective protection of D-arabinose at the 5-OH
group with TBDPS, compounds 10, 11, 12, and 13 were
all obtained in very high yields, thus supporting the
judicious choice of synthetic routes (Figure 2).
Synthesis of Building Block 23
The 1-OH and 2-OH of compound 9 were protected as
an isopropylidene acetal using acetone and anhydrous
cupric sulfate. Compound 18 was obtained in over 90%
yield. The TBDPS group was removed to give 19, which
was benzylated at the 3- and 5-positions to give fully
protected 20. The isopropylidene group was removed
with acetic acid and the resulting compound 21 was
converted to the building block 23 in two steps
(Figure 2).
Synthesis of Compound 27
With the three donors in hand, preparation of the target
oligosaccharide was accomplished as described in Fig-
ure 3. Tetrasaccharide 24 was assembled using com-
pounds 13 and 23 as the donors. Removal of the benzoyl
group converted compound 24 to a suitable acceptor for
O-2 glycosylation. The fully protected pentamer with the
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Chemical synthesis of the building blocks
used in the synthesis of the target pentamer.
The reagents used were added at the indi-
cated intermediates. Key intermediates
were compounds 8 and 13 (A) and 23 (B).
The synthetic procedures are described in
Experimental Procedures. Most of the reac-
tions are based on the use of suitable pro-
tecting groups described in the literature
(cited in the text).terminal sugar in b-anomeric configuration was ob-
tained when the final glycosylation was performed at
278C in the presence of N-iodosuccinimide and silver
trifluoromethanesulfonate. The structures of all com-
pounds were confirmed by NMR (1H and 13C) and, spe-
cifically, introduction of the b-anomeric Araf residue in
compound 26 was confirmed by chemical shift dH-1
5.10; dC-1 100.6, in contrast to a-anomerics centered at
dC-1 106.7 (3), 105.3, respectively. Electrospray mass
spectral analysis of 27 yielded a positive ion at m/z
813 (M + Na)+ corroborating for C33H58O21. Linkage anal-
ysis (gas chromatography-mass spectrometry) indi-
cated that compound 27 had t-Araf, 2-Araf, and 5-Araf.
Enzymatic Assays
The pentamer 27 was tested for its ability to act as an
acceptor substrate for arabinosyltransferase activity in
a cell-free assay using p[14C]Rpp (which is converted
by the cell wall membrane fraction to DPA) as an indirect
arabinosyl donor. When a mixture of the membrane-
and cell wall-enriched fraction was incubated withp[14C]Rpp and compound 27, a reasonable amount
(4%–6% of the p[14C]Rpp used) of radiolabeled material
was found in the 1-butanol extract with a significant
amount of radioactivity remaining in the water layer.
When compound 27 was omitted from the reaction mix-
ture, only trace amounts of radioactivity equivalent to
background level were found in the 1-butanol extract,
and a reduced amount of radioactivity was associated
with the water layer. This indicated that the product
formed had an affinity for organic solvent despite addi-
tion of sugar(s). The reaction was proportional with
time up to 40 min (Figure 4A), and subsequent reactions
were terminated after 20 min. Incorporation of radioac-
tivity into the 1-butanol extract was also linear with re-
spect to protein up to a concentration of 0.8 mg/ml.
There was no significant increase of activity with in-
creasing protein concentrations above this amount
(Figure 4B). The reaction could be saturated with re-
spect to the concentration of compound 27 at about
0.5 mM with a slight reduction in activity at 1 mM (Fig-
ure 4C). An apparent Km of 2.3 mM can be calculated
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Protected thiocresyl glycosides (Figure 2)
were sequentially added to build the inner
trimer (compound 17) at the C-5 hydroxyl
group. Compound 23 (Figure 2), carrying
a benzoyl group at the 2-position, was then
added. Debenzoylation followed by glyco-
sylation with 3 at 278C yielded the pen-
tamer containing the terminal sugar in the
b configuration. The reagents were added
at the indicated intermediates of glycan
synthesis.from these data, assuming that there is substrate inhibi-
tion. This assumption is supported by the observation
that at a concentration of 2 mM of compound 27, the
incorporation of radioactive material into the 1-butanol
extract was reduced to 10% of maximal (data not
shown). The concentration of the indirect donor of arab-
inose residues (p[14C]Rpp) used was 3.8 mM and conse-
quently the concentration of the direct arabinose donor
(DPA) was probably much less. In addition, the endoge-
nous synthesis of DPA relies on a number of enzyme
activities and thus the concentration of this intermediate
could not be efficiently manipulated. In a typical reac-
tion, product was extracted with ethanol and excess
p[14C]Rpp was removed by passing through a strong
anion exchange column (SAX) to remove p[14C]Rpp.
The ethanol eluate was dried and the residue was parti-
tioned between water-saturated 1-butanol and water.
All assays were performed in duplicates and typically
afforded 4%–6% incorporation of radioactivity into the
product. Thin-layer chromatography (TLC) analysis did
not reveal any product formation when the enzyme
source was used from either the embA or embB
mutants. When equal amounts of membrane and P60
(based on protein estimation) from each of the embA
and embB mutants were combined in the assay, a
normal level of product formation was observed (Fig-
ure 5A). These data clearly indicate that the EmbA and
EmbB proteins are responsible for arabinosyltransfer-
ase activity and that these proteins function together.Characterization of the Arabinosyltransferase
Reaction Product
The 1-butanol soluble material was analyzed by TLC and
autoradiography, which revealed thepresenceofasingle
slower migrating new product in comparison to starting
compound 27, suggesting that the oligosaccharide had
increased in size (Figure 5B). To confirm that [14C]arabi-
nose had been added to the acceptor, an aliquot of the
1-butanol-soluble material (w5000 dpm) was hydrolyzed
with 2 M TFA and the hydrolysate was subjected to TLC.
Autoradiography showed that the radioactivity was
exclusively associated with arabinose (Figure 5C).
However, neither the mobility of the de novo synthe-
sized neoglycolipid nor the sugars liberated after com-
plete hydrolysis indicated whether there were one or
two arabinosyl residues incorporated on the pentamer
27, or the nature of the linkage. If one Araf residue
were incorporated, the product formed would be
a hexamer, and would be resistant to C. gelida endoar-
abinanase digestion. In contrast, if two residues of
Araf were incorporated, the product would be a hep-
tamer which would be amenable to the endoarabina-
nase digestion [16] leading to the formation of well-
characterized Ara6 (Figure 6B, peak 2) as was liberated
from [14C]Glc-labeled AG [19].
When the de novo synthesized product was subjected
to endoarabinanase digestion followed by Dionex high
pH anion exchange chromatography (HPAEC) using
the radioactive detector, the digested material eluted
Mycobacterial Terminal Arabinosylcapping Activity
791with the same retention time as authentic Ara6
(Figure 6B, peak 2) released from radiolabeled AG
(Figure 6A). No Ara2 was obtained from the endoarabina-
nase digestion of the de novo product.
Figure 4. Time-Dependent Incorporation of Radioactivity in the En-
zymatic Product and Effect of Protein and Acceptor Concentrations
on the Rate of Product Formation
(A) Incorporation of radiolabeled [14C]arabinose into product rela-
tive to time. At the indicated time points, the reactions were termi-
nated by the addition of ethanol (200 ml), the supernatant was sub-
jected to SAX columns, and extractions were counted for
radioactivity. Concentration of the product formed was calculated
from the counts (in dpm).
(B) Incorporation of radioactivity into the product relative to protein
concentration. Four sets of reactions were performed, each having
different protein (membrane + P60) concentrations (0.4, 0.8, 1.6,
and 3.2 mg). The ratio of membrane to P60 was maintained as in
the basic arabinosyltransferase assay. All other reaction conditions
were identical to the basic arabinosyltransferase assay.
(C) Assays were performed at nine different substrate concentra-
tions (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1, and 2 mM), keeping all other
reaction conditions similar. Control experiments without addition of
any acceptor were also performed in parallel. The data obtained
were subjected to nonlinear regression analysis using GraFit 5.0.Further confirmation of the characteristics of the
endoarabinanase liberated radiolabeled product was
sought from TLC/autoradiography. Unlabeled AG from
M. smegmatis was digested with endoarabinanase,
and the digest was subjected to HPAEC using a
Figure 5. TLC Analysis of Pentamer 27 and the De Novo Product
(A) The reactions were set as M. smegmatis wild-type (lanes 1 and
2); embA mutant (lanes 3 and 4); embB mutant (lanes 5 and 6); and
embA mutant + embB mutant (lanes 7 and 8). Lanes 1, 3, 5, and 7
are reactions without the addition of acceptor, and lanes 2, 4, 6,
and 8 are reactions with acceptor. Lane 7 and 8 reactions con-
tained equal amounts of protein membrane (0.25 mg each) and
P60 (0.15 mg each) from embA and embB mutants. A 500 dpm
aliquot of the product labeled with p[14C]Rpp from the eluate after
the SAX column followed by 1-butanol extraction (Experimental
Procedures) was applied to a TLC plate developed in CHCl3:
MeOH:1 M NH4OAc:NH4OH:H2O (180:140:9:9:23) and then exposed
for 10 days.
(B) The starting material 27 was visualized after spraying with a-
naphthol (lane 1); the radioactive product without (lane 2) or with
(lane 3) acceptor was revealed by autoradiography. A 1000 dpm
aliquot of the product labeled with p[14C]Rpp from the ethanol
eluate after the SAX column followed by 1-butanol extraction
(Experimental Procedures) was applied to a TLC plate developed
in CHCl3:MeOH:1 M NH4OAc:NH4OH:H2O (180:140:9:9:23) and then
exposed for 4 days. The migration of the enzymatically synthesized
product was slower than pentamer 27.
(C) Radioactive AG (5000 dpm; lane 1) and the de novo product
(lane 2) were hydrolyzed with 2 M TFA, the acid removed by evap-
oration, reconstituted in 25 ml of water, and applied to TLC. The
chromatogram was developed in pyridine:ethyl acetate:acetic
acid:water (5:5:1:3) and subjected to autoradiography.
Chemistry & Biology
792preparative column. The Ara6 liberated was collected
and desalted with an on-column carbohydrate mem-
brane desalter (Dionex), and residual salt was removed
using a Biogel P-2 column. Ara6 released from the de
novo product was analogously purified and both were
applied to the TLC/autoradiography. The cold Ara6 (con-
firmed using mass spectrometry) [16] and the labeled
Ara6 material comigrated, suggesting that they were
the same compounds (data not shown).
This conclusion was further substantiated by periodate
oxidation/Smith degradation. This procedure [20] should
remove the two t-Araf residues from the branched Ara6,
convert the 5-linked reducing arabinose to ethylene gly-
col, and yield a smaller oligosaccharide core from the
remaining Araf residues, the structure of which is shown
in Figure 7 (inset). When Ara6 isolated from AG that had
been radiolabeled in vivo and the enzymatically synthe-
sized product were subjected to Smith degradation, the
products formed coeluted and had a retention time of
32 min (Figure 7), earlier than that of Ara6 on HPAEC.
Discussion
The central role of arabinan in the cell wall proper ap-
pears to be in maintaining its integrity by tethering the
Figure 6. HPLC Analysis of Ara6
(A) Base-solubilized [14C]AG, 10,000 dpm from M. smegmatis
mc2155 cells [33], was digested with endoarabinanase as
described, dried, reconstituted in 10 ml of water, and subjected to
HPLC fitted with a Dionex Carbopac PA-1 column and a radioactive
detector. Oligosaccharides were eluted with a gradient of sodium
acetate (0–1 M) in 10% sodium hydroxide. Peaks labeled 1, 2,
and 3 are Ara2, Ara6, and cyclic Gal4, respectively. Identities of
these peaks have been established earlier [37].
(B) Analogous conditions as for labeled AG were applied to the
enzymatically synthesized product.parallel packed outer mycolic acid lipid barrier perpen-
dicular to the underlying peptidoglycan through the flex-
ible glycosyl linkages of AG. The ability of mycobacteria
to synthesize AG is critical to its viability. Based on the
linkages present and arrangement of various glycoside
residues, one can speculate that a number (perhaps
six or seven) of arabinosyltransferases are involved in
the assembly of the arabinan chain(s) of mycobacterial
AG [21]. However, only three proteins (EmbA, EmbB,
and EmbC) have been directly implicated in arabinan
synthesis in mycobacteria [14, 15, 22]. Only recently,
a fourth arabinosyltransferase, AftA, has been identified
and shown to donate the first arabinose to the galactan
backbone in Corynebacterium glutamicum [23]. Unlike
Mycobacterium species, C. glutamicum has only one
emb gene which is reported to be able to donate [24]
multiarabinosyl residues with different linkages.
It had been suggested that these proteins transfer the
D-Araf residues from DPA onto the growing arabinan
[14]. Based on detailed structural studies on LAM and
AG from the embA/embB mutants of M. smegmatis,
we have previously shown that EmbA and EmbB are in-
volved in the synthesis of the disaccharide b-D-(1/2)-
a-D-Araf on the 3-arm of the linear Arab1/2Araa1/
5Araa1/5Araa1/ in M. smegmatis [15]. Although the
structural data were sound, we lacked the ability to as-
say for the putative activity of EmbA/EmbB.
In order to develop an arabinosyltransferase assay
and to pinpoint the functional aspect of EmbA and
EmbB, we synthesized an arabinose-based acceptor.
The formation of oligosaccharide in high yield [25–27]
and its use in the development of a mycobacterial arabi-
nosyltransferase cell-free assay have previously been
described [28], and there have been a number of elegant
studies in recent years that describe efficient syntheses
of furanosidic oligosaccharides related to mycobacte-
rial cell wall arabinan leading to formation of oligosac-
charides in high yield [18, 29–31]. To assess the role of
the EmbA and EmbB proteins in the transfer of the
disaccharide b-D-Araf-(1/2)-a-D-Araf intermediate
involved in the formation of the terminal Ara6, in the
Figure 7. HPLC Analysis of Periodate Oxidation of Products
Radiolabeled Ara6 from AG and Ara6 released from the de novo
product were isolated and subjected to a Smith degradation as
described in Experimental Procedures. The samples were then
analyzed by HPLC as in Figure 6. The inset shows the structure
of the compound formed after Smith degradation. The down arrow
at w35 ml corresponds to residual Ara6.
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ceptor with the structure shown schematically in Fig-
ure 3, compound 27, preserving the specific linkages
and anomeric configurations. In designing the synthetic
route to the target compound, we adapted an approach
that could readily give a series of building blocks that
could be assembled sequentially in order to provide
the target linear pentamer 27. With the building blocks
in hand, all glycosylation reactions were carried out
with an appropriate thioglycoside donor and octyl gly-
coside acceptor in the presence of N-iodosuccinimide
and silver triflate [32]. The stereoselectivity of synthesis
was determined by 13C and 1H NMR. Typically, the a-
anomers resonated between d109 and 106 ppm,
whereas the b-anomer appeared at d100.8 ppm. The
main problem encountered during the course of chemi-
cal synthesis was that a mixture of a:b anomers was ob-
tained in the synthesis of compounds 14 and 16 which
required tedious chromatographic separation. This is
due to the presence of a benzyl group at the 2-OH posi-
tion of the donor. However, we maintained our strategy,
as only a one-step deprotection would be required after
assembly of the fully protected pentasaccharide. We
also noticed that trace amounts of thiocresol remaining
after purification of compounds 4 and 26 killed the Pd/C
catalyst required for debenzylation, leading to low yields
of 5 and 27.
The molecule was designed such that it would serve
as an acceptor substrate for the addition of Araf resi-
dues by specific arabinosyltransferases, allowing us to
probe the question of whether EmbA or EmbB was di-
rectly involved in the terminal Ara6 formation. The en-
zyme activity assays and product analyses clearly dem-
onstrated that EmbA and EmbB were involved in the
transfer of two Araf residues to the acceptor 27 in the
cell-free system. However, the knockout mutants had
detrimental effects; that is, the addition of Araf residues
to compound 27 was not detected by TLC analysis. This
closely mirrored the in vivo phenotype of the arabinan
determined in the EmbA and EmbB disrupted mutants
[15]. The fact that neither the individual embA nor
embB mutants could arabinosylate the acceptor effi-
ciently and, more importantly, that arabinosylation was
restored as in the wild-type upon mixing the enzyme
sources from two individual strains, suggests that both
proteins must be present for detectable activity in our
assay. Therefore, it seems unlikely that either EmbA or
EmbB protein by itself is an Araf transferase. It is possi-
ble that the two proteins act in coordination to add the
first Araf residue to compound 27 and that a third protein
(yet to be identified) adds the second residue.
Another hypothesis is that the terminal b-D-Araf-(1/
2)-a-D-Araf disaccharide is presynthesized by ‘‘helper’’
enzymes and transferred in its entirety by the EmbB/
EmbA functioning as a heterodimer. It is also possible
that the Emb proteins are multifunctional and assemble,
transfer, and/or transport the disaccharide. There could
be multiple intermediate steps prior to the formation of
b-D-Araf-(1/2)-a-D-Araf and then only the transfer will
occur, for instance, (1) synthesis of the unique b-D-
Araf, (2) transfer of the b-D-Araf to the 2-position of an-
a-D-Araf, and (3) transfer of the disaccharide onto the
3-arm of the 3,5-a-D-Araf. The role of EmbA and EmbB
in mycobacteria is distinct from the role of the singleEmb protein (Cg-emb) in Corynebacterium even though
they share high homology [24]. Cg-emb is responsible
for deposition of the majority of arabinan in AG (all but
three residues) in Corynebacterium. It seems unlikely
that if both EmbA and EmbB were absent a similar
lack of arabinosylation of AG would occur.
Attributing functional properties to the Emb proteins
will require synthesis of various specific neoglycolipid
Araf acceptors and continued analyses for acceptor ac-
tivity. Attempts are also being made to generate double-
knockout strains in M. smegmatis, such that functional-
ity of these proteins can be addressed with a cleaner
background.
Significance
In this study, we demonstrate unambiguously that
a mycobacterial cell-free preparation from wild-type
M. smegmatis transfers two Araf residues from the do-
nor pR[14C]pp to the synthetic substrate, forming
a nonreducing terminal disaccharide, b-D-Araf-(1/
2)-a-D-Araf characteristic of the mycobacterial ara-
binan of AG. This transferase activity is not detectable
in strains of M. smegmatis where either the embA or
embB gene has been genetically disrupted, and is re-
stored upon mixing the enzyme source from the two
disrupted strains. These findings suggest that both
EmbA and EmbB are required in the synthesis/transfer
of the disaccharide to yield the terminal Ara6 motif
of AG.
This is the first description providing evidence for
the role of the EmbB/EmbA protein in the formation
of the crucial terminal Ara6 in AG. These two proteins
in a way contribute to the transfer and completion of
the disaccharide b-D-Araf-(1/2)-a-D-Araf on a syn-
thetic linear pentasaccharide. The results are in com-
plete agreement with the phenotypic changes ob-
served for EmbA and EmbB deleted mutants. The
mycobacterial arabinosyltransferases are unique and
attractive targets for developing new antimicrobial
therapeutics. Our work paves the way for probing for
numerous arabinosyltransferases that should logi-
cally be present in the assembly of complexmolecules
such as arabinan of LAM and AG.
Experimental Procedures
A preparation of p[14C]Rpp (300 mCi/mmol) was generated from uni-
formly labeled D-[14C]glucose (American Radiolabeled Chemicals)
as described [10]. ATP, MOPS, 2-mercaptoethanol, DNase (type I),
and RNase (type I) were purchased from Sigma. Percoll (sterile)
was purchased from Pharmacia. Biogel P-6 and P-2 were obtained
from Pharmacia. Authentic pure Ara6 was obtained after enzyme
digestion of AG followed by collecting the relevant peak eluting off
Dionex HPAEC and immediate desalting by passage through a
Biogel P-2 column. Radiolabeled Ara6 was isolated from radiola-
beled AG purified fromM. smegmatis that was metabolically labeled
as previously described [33]. Protein concentrations were deter-
mined using the BCA assay (Pierce). All compounds synthesized
are distinguished in bold type font.
Organic Synthesis and Analysis
All chemicals were purchased from Sigma-Aldrich and were used
without further purification. Thin-layer chromatography (TLC) was
performed on silica gel G 60 (EM Science) aluminum-backed plates.
Column chromatography was performed using silica gel (70–230
mesh) and Iatrobeads (beaded silica gel 6RS8060) (Iatron
Chemistry & Biology
794Laboratories, Tokyo). Unless otherwise stated, all reactions were
performed at room temperature under argon. Drying after organic
extractions was done over anhydrous Na2SO4.
1H and 13C NMR spectra for the synthetic compounds were mea-
sured on a Varian-Inova 300 or 400 spectrometer. Electrospray (ESI)
and fast atom bombardment mass spectrometry (FAB-MS) were
performed on Thermo-Finnigan LCQ Duo and VG Autospec mass
spectrometers, respectively. High pH anion exchange chromatogra-
phy (HPAEC) was performed on a Dionex LC system fitted with a
Dionex Carbopac PA-1 column, and the oligosaccharides were
eluted using a gradient of 0–1 M sodium acetate in 10% sodium
hydroxide and detected with a pulse-amperometric detector (PAD).
For chemical synthesis, donors and acceptors were synthesized
independently as building blocks as shown in Figures 2 and 3. The
two donors 13 (p-cresyl 2,3-di-O-benzyl-5-O-tertbutyldiphenylsilyl-
1-thio-a-D-arabinofuranoside) and 23 (p-cresyl 2-O-benzoyl-3,5-
di-O-benzyl-1-thio-a-D-arabinofuranoside and the acceptor 8 octyl
2,3-di-O-benzyl-a-D-arabinofuranoside were synthesized following
documented procedures [28, 34, 35] with variations as needed.
The inner trisaccharide 17 was built on the acceptor 8, which served
as a template for the addition of compound 23, to yield tetramer 24 in
95% yield. Selective removal of the benzoyl group from the 2-OH po-
sition of 24 yielded an intermediate 25 suitable for b-glycosylation
[35] to give the fully protected pentamer 26 in 89% yield: Rf 0.15
(hexane:EtOAc, 4:1); 1H NMR (300 MHz, CDCl3): d7.37–7.21 (m,
55 H), 5.15 (s, 1 H), 5.13 (s, 1H), 5.11 (s, 2 H), 5.10 (s, 1 H), 4.81–4.37
(m, 22 H), 4.25–4.01 (m, 10 H), 3.94–3.82 (m, 4 H), 3.74–3.66 (m, 4 H),
3.58–3.52 (m, 8 H), 3.42–3.34 (m, 1 H), 1.60 (m, 2 H), 1.29 (m, 10 H),
0.90 (m, 3 H). 13C NMR (75 MHz, CDCl3): d138.5, 138.4, 138.3, 138.0,
137.9, 137.8, 128.7, 128.6, 128.6, 128.5, 128.3, 128.2, 128.0, 127.9,
127.8, 106.7, 105.3, 100.6, 88.7, 88.5, 85.9, 84.5, 84.2, 83.6, 83.4,
83.2, 81.8, 80.8, 80.2, 73.5, 73.3, 72.6, 72.5, 72.4, 72.2, 70.3,
69.0, 68.0, 66.2, 65.8, 32.1, 30.0, 29.7, 29.6, 26.4, 22.9, 14.4. FAB-
MS calculated for [C110H124O21] 1782.15, found 1782.1.
Compound 27
Debenzylation in the presence of Pd/C gave the desired product
(49%), which was found to be extremely water soluble. Rf 0.78
(CHCl3:MeOH:H2O, 10:10:3)
1H NMR (400 MHz, D2O): d 5.14 (s, 1 H),
5.11 (d, 1 H, J = 3.6 Hz), 5.08 (s, 1 H), 5.05 (s, 1 H), 4.97 (s, 1 H),
4.16–3.95 (m, 15 H), 3.84–3.60 (m, 12 H), 1.57 (m, 2 H), 1.25 (m,
10 H), 0.85 (m, 3 H). FAB-MS calculated for [C33H58O21]Na
+ 813.35,
found 813.3.
Preparation of Mycobacterial Membranes and P60
Wild-type and embB and embA mutants of M. smegmatis mc2155
cells were grown in nutrient broth (Difco Laboratories) to mid-log
phase (OD 0.7–0.8). Cells (w8–10 g wet weight) were harvested by
centrifugation, washed, and resuspended in ice-cold buffer A con-
taining 50 mM MOPS (pH 8.5), 5 mM 2-mercaptoethanol, 10 mM
MgCl2, 150 mg/ml DNase, and 250 mg/ml RNase. Cells were disrup-
ted by six to seven passages through a French press at 1500 psi.
The suspension was centrifuged at 27,000 3 g for 60 min at 4C.
The mycobacterial cell wall pellet was removed and the supernatant
was recentrifuged at 200,000 3 g for 2 hr at 4C. The supernatant
was discarded and the pellet of enzymatically active membranes
was gently resuspended in 500 ml of buffer A; the resulting protein
concentrations of the membrane fractions were typically between
15 and 20 mg/ml. The 27,000 3 g pellet was suspended in 10 ml of
buffer A and Percoll was added to achieve a 60% suspension. The
suspension was mixed and centrifuged at 27,000 3 g for 60 min at
4C. The resulting flocculent, white layer was collected and washed
three times with buffer A at 12,000 3 g to yield a cell wall-enriched
fraction (P60). This fraction was resuspended in 1 ml of buffer A to
yield a protein concentration of 5–6 mg/ml.
Arabinosyltransferase Assays
Typical reaction mixtures contained 40 mM MOPS (pH 8.0), 4 mM
2-mercaptoethanol, 8.5 mM MgCl2, 1 mM ATP, 3.8 mM p[
14C]Rpp
(500,000 dpm), the indicated concentrations of acceptor (compound
27), and membranes and P60 in a total volume of 200 ml. The reaction
mixtures were incubated at 37C for 1 hr and then terminated by
adding 200 ml of ethanol. The resulting mixture was centrifuged at
14,000 3 g, and the supernatants were loaded onto prepackedstrong anion exchange (SAX) columns (Burdick and Jackson). The
columns were eluted sequentially with 2 ml each of 50% ethanol
and water. The eluate was evaporated to dryness and partitioned
between the two phases (1:1) of water-saturated 1-butanol and wa-
ter. The 1-butanol fractions were measured for radioactive incorpo-
ration by liquid scintillation spectrometry. Assays were carried out
under conditions where synthesis was linear for both time and
protein concentration. Values reported are averages of duplicate
reactions from representative experiments. Kinetic constants
were determined by nonlinear regression analysis using GraFit 5.0
(Erithacus Software).
Analytical Procedures
For TLC analysis of the enzymatically synthesized, radiolabeled
product, an aliquot of the 1-butanol extract was dried under nitrogen
and the residue was dissolved in methanol for analysis by silica gel
TLC. The plates were developed in CHCl3:MeOH:1 M NH4OAc:
NH4OH:H2O (180:140:9:9:23) followed by autoradiography at270
C
using Biomax MR1 film (Kodak), and compound 27 was visualized
using a-naphthol spray reagent. For analysis of the sugar composi-
tion of the radiolabeled product, approximately 5000 dpm of the
1-butanol-soluble material was dried under nitrogen and hydrolyzed
in 200 ml of 2 M trifluoroacetic acid (TFA) at 120C for 2 hr. The TFA
was removed under a stream of air, and the hydrolysate was
analyzed on a silica gel TLC plate developed in pyridine:ethyl
acetate:acetic acid:water (5:5:1:3) followed by autoradiography as
described above. Radioactive spots were identified by cochro-
matography with standard sugars, which were visualized using
a-naphthol spray.
Radiolabeled products from the enzyme assays were subjected to
digestion with endoarabinanase isolated from C. gelida [16]. In this
case, approximately 10,000 dpm of the 1-butanol-soluble material
was dried under nitrogen, reconstituted in 10 ml of water, sonicated,
and treated with endoarabinanase for 16 hr at 37C as previously
described [36]. Aliquots from the digested mixture containing the
released oligoarabinofuranosides were subjected to Dionex HPAEC.
Radioactivity was quantitated by liquid scintillation spectrometry.
The endoarabinanase-treated radioactive material was also
subjected to Smith degradation (periodate oxidation) as previously
described [16, 20]. Briefly, enzymatically radiolabeled, endoarabina-
nase-treated digestion product (10,000 dpm) was purified by size
exclusion chromatography on Biogel P-6. This material and authen-
tic Ara6 isolated from endoarabinanase-digested radiolabeled AG
were subjected to periodate oxidation (0.15 M) for 72 hr. Ethylene
glycol was added to terminate the reaction. The oxidized product
was desalted on a Biogel P-2 column and reduced with sodium bor-
odeuteride. After removal of the borate after coevaporation with
methanol, the residue was subjected to mild acid hydrolysis (1 N
H2SO4) overnight at room temperature and the mixture was neutral-
ized with barium carbonate. The reaction mixture was then centri-
fuged and the supernatant was dried, dissolved in water, desalted,
and analyzed by Dionex HPAEC and TLC.
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